Xenetic Biosciences, Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update

Author's Avatar
Aug 12, 2022

Second quarter marked by deal to in-license DNase-based oncology platform which expands pipeline with well-defined and accelerated path to clinic